SciBase Secures SEK 11 Million Through Directed Share Issues
SciBase Moves Forward with New Share Issuance
The board of directors of SciBase Holding AB (publ) has decided to proceed with a new share issue, aiming to raise approximately SEK 11 million. This decision aligns with the company’s ongoing strategy to leverage financial resources for growth and development in the medical technology sector.
Company Overview and Technology Focus
SciBase is renowned for its innovative AI-driven platform, Nevisense, which is pivotal for early detection and prevention of dermatological conditions. By utilizing advanced electrical impedance spectroscopy (EIS), this user-friendly tool enhances diagnostic accuracy for healthcare providers, ensuring swift intervention for serious issues such as skin cancer. The company is committed to improving patient outcomes by empowering physicians with precise diagnostic tools.
Rapid Growth in the US Market
In recent years, SciBase has made significant strides in the American market, attributing nearly 75% of its market potential to this region. The results have been promising, with a remarkable sales growth rate of 177% in 2024 and an astounding 306% growth in the first quarter of 2025 compared to the previous year. The strategic enhancement of its US subsidiary, including the addition of new sales personnel and expanding regional representation, underlines its dedication to establishing Nevisense as the primary choice for skin assessment.
Collaborations and Future Endeavors
Further strengthening its market position, SciBase has collaborated with leading Key Opinion Leaders (KOLs) in the US, which has led to the endorsement of Nevisense through a consensus report highlighting its efficacy in improving diagnostic assessments. Alongside this, the company aims to improve reimbursement frameworks with insurance providers to integrate Nevisense into clinical practice guidelines fully.
Details of the Directed Share Issues
The recent resolution to conduct a directed share issue allows SciBase to raise capital without preferential rights to existing shareholders, thus ensuring the involvement of strategic investors. The initial fundraising, Directed Issue I, targets SEK 19 million and involves the issuance of up to 47,886,950 new shares. Following this, the new Directed Issue II will raise SEK 11 million, with a maximum of 28,000,000 new shares being offered. This approach provides the company the flexibility to maintain a dynamic capital structure.
Future Financial Implications
The proceeds from these share issues will be utilized for various key initiatives, including the growth of commercialization efforts in the US, investment in product development, and sustaining working capital for ongoing operations. The subscription price is set at SEK 0.40 per share, determined through comprehensive discussions and market analysis that reflect the current economic conditions.
Expansion of Shareholder Base
By omitting preferential rights, SciBase aims to widen its strategic ownership base, fostering stronger partnerships with future investors. The board determined that an equity raise through rights issues would be less favorable due to the time and costs involved, allowing for a quicker and more efficient fundraising process.
About SciBase
SciBase is a global leader in medical technology, pioneering innovations in dermatology through its flagship product, Nevisense. With more than two decades of research behind its development, the company strives to reduce patient suffering while enhancing diagnostic capabilities for healthcare professionals. As a publicly listed entity on Nasdaq First North Growth Market since 2015, SciBase continues to make significant contributions to the field of dermatology.
Frequently Asked Questions
What is the purpose of SciBase's directed share issue?
The directed share issue aims to raise SEK 11 million to finance growth strategies, particularly in the US market, enhancing product development and working capital.
How has SciBase performed in the US market recently?
SciBase has reported an impressive 177% sales growth in 2024 and a 306% quarter-on-quarter increase in 2025, highlighting its strong market presence.
What technology does Nevisense use?
Nevisense utilizes artificial intelligence and electrical impedance spectroscopy (EIS) to improve the accuracy of skin disease diagnostics.
Who are the main investors in the directed share issue?
The directed share issue will see investment from existing shareholders, including Haga Gruppen Holding AB and Life Science Invest Fund 1 ApS.
What future developments can be expected from SciBase?
SciBase is focused on expanding its product range, enhancing reimbursement structures for Nevisense, and increasing its market footprint in dermatology.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
